Twice-Yearly HIV Injection Shows 99% Success in Trials

Scientists have created a twice-yearly injection that prevents 99% of new HIV infections, offering hope to millions worldwide and proving how long-term research investments pay off.

The drug lenacapavir began with a 1996 discovery at the University of Utah. Biochemist Wesley Sundquist mapped the protective shell of the HIV virus and found that tiny disruptions could stop it from spreading. His lab received 12 years of funding from the National Institutes of Health to pursue this basic science.

That foundational work caught the attention of pharmaceutical company Gilead Sciences in 2006. Nearly 20 years later, their clinical trials demonstrated remarkable results. The PURPOSE-1 trial showed 100% prevention, while PURPOSE-2 achieved 99% effectiveness.

The FDA approved lenacapavir in June 2025, marking a potential turning point in the global fight against HIV. The drug's twice-yearly dosing schedule makes it far easier to use than daily pills, which could dramatically improve access and adherence.

The Ripple Effect

This breakthrough highlights how public and private sectors work together to save lives. Every single drug approved by the FDA in the 2010s involved research funded by the NIH. The public sector invests in basic science because it takes decades to show results, making it too risky for companies to fund alone.

The economic returns are striking too. Each dollar of NIH-funded research generated $2.56 in economic activity during the 2024 fiscal year. That's a 156% return on investment beyond the medical breakthroughs themselves.

Public funding also drives health equity by supporting research on diseases affecting underserved communities. The NIH funds work on neglected tropical diseases like Chagas disease and leishmaniasis, conditions that rarely attract private investment. In 2023, they launched community-led research programs addressing structural factors that affect health outcomes in disadvantaged areas.

Without sustained federal support, discoveries like lenacapavir become far less likely. The pathway from Sundquist's lab to an FDA-approved drug took nearly 30 years of patient, persistent work funded by taxpayers believing in science's power to improve lives.

This breakthrough reminds us that today's curiosity-driven research becomes tomorrow's life-saving treatment.